i-SENS’s CareSens Air CGM Secures Belgian Reimbursement, Paving the Way for Expanded European Market Penetration

June 20, 2026

i-SENS (アジア経済新聞経由) South Korea, ベルギー

Overview

South Korean medical device firm i-SENS has achieved a critical milestone with its “CareSens Air” continuous glucose monitoring (CGM) device, securing public insurance reimbursement in Belgium. Listed under the Belgian National Institute for Health and Disability Insurance (INAMI)’s diabetes agreement, this designation establishes a robust sales foundation and enhances accessibility for Belgian patients. The move is central to i-SENS’s strategy to accelerate its global CGM business expansion, with deployments planned in over nine countries this year.

In Depth

Key Development

South Korean medical device leader i-SENS has announced that its continuous glucose monitoring (CGM) device, “CareSens Air,” has been officially added to the reimbursement list under the diabetes agreement by the Belgian National Institute for Health and Disability Insurance (INAMI). This designation ensures that CareSens Air will be covered for patients through Belgium’s public healthcare insurance system, significantly boosting the product’s market penetration and patient accessibility within the country. This strategic inclusion is a cornerstone of i-SENS’s broader initiative to accelerate the global expansion of its CGM business.

Technical and Clinical Profile

CareSens Air is a sophisticated CGM system that integrates a compact, wearable sensor with a dedicated smartphone application. It provides real-time, continuous glucose level measurements, transmitting data to a paired smartphone or other compatible devices. This system empowers diabetes patients to meticulously track daily blood sugar fluctuations, thereby gaining insights into the impact of diet, exercise, and medication on their glucose dynamics. INAMI’s decision to list CareSens Air for reimbursement underscores the device’s adherence to stringent Belgian medical standards and its demonstrated clinical utility. This will significantly lower the financial barrier, granting Belgian diabetes patients access to advanced glucose monitoring technology.

Market Context and Global Trends

The escalating global prevalence of diabetes has markedly increased the significance of continuous glucose monitoring (CGM) in facilitating effective patient self-management. Across numerous European nations, the expansion of insurance reimbursement for CGM devices is acting as a pivotal catalyst for market growth. INAMI’s decision in Belgium aligns with this broader trend, seeking to elevate the quality of diabetes care by promoting the adoption of clinically validated, high-quality CGM solutions. i-SENS is strategically leveraging this momentum, with plans for new market deployments in over nine countries this year, including Belgium, to solidify its footprint in the global CGM landscape.

Strategic Implications and Future Outlook

The reimbursement of CareSens Air in Belgium constitutes a vital strategic foothold for i-SENS’s European market entry. With comprehensive insurance coverage, Belgian physicians can confidently prescribe the device, while patients benefit from significantly reduced financial barriers, thereby accelerating adoption rates. This success could exert a positive influence on subsequent reimbursement negotiations across other European countries, substantially enhancing i-SENS’s competitive standing in the global CGM market. The company reaffirms its commitment to improving the quality of life for diabetes patients through continuous research and development alongside sustained market expansion initiatives.

Source: https://www.asiae.co.kr/en/article/2026061108383407615

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.